Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

News

Long-Term Health-Related Quality of Life With Adjuvant Pembrolizumab in Stage III Melanoma
Novel Triplet Under Study for Metastatic NSCLC: Early Phase II Results
Survival Outcomes in BRAF-Mutant Melanoma: BRAF/MEK vs PD-1 Inhibitors
Atezolizumab Before and After Chemoradiation: Novel Plan for Unresectable Stage III NSCLC
Early Results of Combination Regimens With Pembrolizumab in Melanoma
4-Year Follow-up on Lenvatinib Plus Pembrolizumab in Advanced Melanoma
Chemotherapy-Free Combination Approved by FDA for EGFR-Mutated NSCLC
How Intratumoral Bacteria Might Improve Outcomes With Immunotherapy for NSCLC
Nivolumab Plus Relatlimab in Melanoma: 3-Year Survival Outcomes From RELATIVITY-047
FDA Approves Use of Durvalumab With Chemotherapy Before and After Surgery in NSCLC
Novel Immunotherapy Combination After Anti–PD-1 Therapy Fails in Advanced Melanoma
Adding Elotuzumab to Lenalidomide Maintenance in Multiple Myeloma
Nivolumab Delivered Through Continuous Intrathecal Infusion for Advanced Melanoma
Is a Fixed 2-Year Duration of Pembrolizumab Treatment Safe in Advanced NSCLC?
Tocilizumab Combined With Nivolumab and Ipilimumab in Advanced Melanoma
Daratumumab and Hyaluronidase-fihj With VRd Approved by FDA for Multiple Myeloma
Exploring Treatment Options for Advanced-Stage Melanoma During Pregnancy
KEYNOTE-629: Long-Term Results With Pembrolizumab in Squamous Cell Skin Cancer
Bispecific Antibody Plus EGFR Inhibitor in EGFR-Mutant Lung Cancer
IL-2–Sparing Tumor-Infiltrating Lymphocyte Cell Therapy for Melanoma
CXCR1/2 Inhibitor Plus Pembrolizumab in Metastatic Melanoma: Early-Phase Trial Results
Easing the Effects of T-DXd: Electronic Symptom Tracking Tested in PRO-DUCE Trial
Neoadjuvant Immunotherapy for Squamous Cell Skin Cancer
Lifileucel Plus Pembrolizumab Active in Melanoma Setting in Phase II Trial
Quality-of-Life Data Support Pembrolizumab’s Role in Early-Stage NSCLC
Novel Monoclonal Antibody and Chemotherapy Under Study in Nonmelanoma Skin Cancer
Vaccine Plus Immunotherapies Under Investigation in Advanced Melanoma
Copyright © 2024 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.